<DOC>
	<DOCNO>NCT00177827</DOCNO>
	<brief_summary>A fixed dosage regimen voriconazole routinely use prophylaxis aspergillosis lung transplant patient institution . We hypothesize use fixed dosage voriconazole regimen lead large degree variability drug exposure among lung transplant patient consequently , therapeutic failure toxicity . This three part study examine plasma lung voriconazole concentration achieve prophylactic regimen assess correlation concentration efficacy toxicity . We aim conduct initial pilot study 12 lung transplant patient characterize pharmacokinetic profile voriconazole intravenous oral dos . The data gather pilot pharmacokinetic study utilized correlate trough concentration total voriconazole drug exposure measure area plasma concentration versus time curve ( AUC ) . Additionally , trough concentration follow nine week prophylactic treatment period large cohort patient determine maintenance consistency trough concentration whether plasma concentration predictive efficacy toxicity . Voriconazole lung concentration measure pilot study 12 patient undergo bronchoscopy procedure part standard medical care order determine relationship plasma lung concentration . The information obtain three phase study utilized characterize pharmacokinetics voriconazole lung transplant patient . Further , use define optimal therapeutic voriconazole regimen individualize target specific concentration lung plasma maximize efficacy minimize toxicity</brief_summary>
	<brief_title>Voriconazole Prophylaxis Against Aspergillosis Lung Transplant Recipients</brief_title>
	<detailed_description>Blood sample ( 5 mL ) collect either exist indwell intravenous catheter via catheter place research nurse phlebotomist . The sample centrifuge 1,500 g 10 minute within 60 minute collection . The plasma separate two separate cryovials store - 80 C time assay Voriconazole.A standardize data collection sheet create study investigator utilize gather pertinent information study participant patient medical record electronic database . The type information collect include , limited , demographic information , transplant history , periodic serum chemistry hematology monitoring , medication regimen , plasma voriconazole level monitoring efficacy safety monitoring parameter .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>Male female lung transplant recipient , great 18 year old , initiated voriconazole prophylactic regimen ( Figure 1 ) transplant physician standard care eligible inclusion study . Patients receive voriconazole treat active fungal infection exclude . Patients concurrently receive medication document affect voriconazole pharmacokinetics exclude . The agent include , may limit follow ; carbamazepine , phenytoin , omeprazole , rifabutin rifampin.10</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>